阿帕替尼治疗软组织肉瘤的疗效观察  

Therapeutic Effect of Apatinib Sarcoma

作　　者：沈娣 茆勇[1] 黄泽波 冯新[2] 徐闻欢[1] SHEN Di;MAO Yong;HUANG Ze-bo;FENGXin;XU Wen-huan(Department of Oncology,The Affiliated Hospital of Jiangnan University,Wuxi No.4 People5 s Hospital,Wuxi,Jiangsu,214062,China;Department of Health Management,Shengli Oilfield Central Hospital,Dongying,Shandong,257034,China)

机构地区：[1]江南大学附属医院肿瘤内科,无锡市第四人民医院肿瘤内科,江苏无锡214062 [2]胜利油田中心医院健康管理部,山东东营257034

出　　处：《中国血液流变学杂志》2018年第4期384-387,共4页Chinese Journal of Hemorheology

基　　金：国家自然科学基金资助项目(81402487).

摘　　要：目的评价阿帕替尼联合化疗一线治疗IV期软组织肉瘤的疗效与安全性。方法回顾性分析8例W期软组织肉瘤一线接受阿帕替尼联合化疗的患者,每治疗2个周期后按实体瘤疗效评价标准(RECIST)评价疗效,同时按常见不良反应事件评价标准(CTCAE)评价安全性。结果所有8例疗效均可评价,其中无CR病例,PR1例,SD6例,PD1例,患者中位PFS6个月,ORR12.5%,DCR87.5%,6个月PFS率50%。IINIV级不良反应中,高血压2例,手足综合症1例,骨髓功能抑制1例,予对照治疗后症状改善。没有不良反应相关的死亡病例。结论阿帕替尼联合化疗可以抑制软组织肉瘤进展,同时具有较好的安全性,有进一步深入探索的价值。Objective To evaluate the efficacy and safety of apatinib combined with chemotherapy in the first line treatment of stage IV sarcoma. Methods We retrospectively analyzed 8 cases of stage IV sarcoma patients who received apatinib combined with chemotherapy as first line therapy. The efficacy was evaluated by RECIST and safety was evaluated by CTCAE every two cycles. Results There were no CR, 1 case was PR, 6 cases were SD and 1 case was PD. The median PFS was 6 months, ORR: 12.5%, DCR: 87.5%, PFS rate was 50% in 6 months. Among the grade III-IV adverse reactions, hypertension was found in 2 cases, hand-foot syndrome in 1 case and bone marrow depression in 1 case. The symptoms were relieved after treatment. There were no deaths associated with adverse reactions. Conclusion Apatinib combined with chemotherapy can inhibit the progression of sarcoma and the combination has good tolerance in patients.

关 键 词：软组织肉瘤 阿帕替尼 化疗 

分 类 号：R738.6[医药卫生—肿瘤] R730.53[医药卫生—临床医学]